A Valuable Tool to Protect Against Influenza A Virus in Swine (IAV-S)

IAV-S is an acute respiratory disease that causes economic losses in pig production. Vaccinating the right animal at the right time can be an important consideration in helping provide reliable protection against the economic losses caused by IAV-S throughout the herd.

The use of key performance indicators, including average daily gain (ADG) and variation (the spread of weights across a group of pigs), is essential in helping assess the success of IAV-S protocols.

Positive impact on key performance measures with Ingelvac Provenza®
In a field study to assess the performance benefit of Ingelvac Provenza® on commercial growing pigs challenged with IAV―S, investigators set out to determine benefits to piglet performance in 2 separate challenge groups of pigs vaccinated between 3 and 5 days of age in the face of maternal antibodies.1

Objective: To determine the difference in weight gain between piglets vaccinated with Ingelvac Provenza® and those left unvaccinated after challenge with a contemporary IAV-S at either 10 weeks or 15 weeks of age.

Investigators: C. Goodell, S. Playter, B. Fergen, R. Plazola (ISU)

Method: Pigs were challenged with a contemporary heterologous IAV-S at either 10 or 15 weeks of age and performance was compared to unvaccinated cohorts.

Significant improvement in ADG
Pigs that were vaccinated with Ingelvac Provenza® at 3 to 5 days of age and then challenged with IAV-S at either 10 or 15 weeks of age had:

  • significantly more weight gain post challenge than non-vaccinates
  • reduced variation than non-vaccinated cohorts

STUDY GROUP 1:
Improvement in ADG in pigs challenged at 10 weeks of age

ADG was significantly higher in vaccinates than non-vaccinates post challenge, with vaccinates gaining 0.36 lb more per day through week 1 (P < 0.001) and 0.27 lb more per day through week 2 (P ≤ 0.003) compared with non-vaccinates.

Vaccinates gained 4.4 lb more than non-vaccinates for the 3 weeks following challenge.


STUDY GROUP 2:
Improvement in ADG in pigs challenged at 15 weeks of age

ADG post challenge was significantly higher, with vaccinates gaining an average of 0.13 lb more per day from D-1 through D14 (end of study) (P ≤ 0.041).

The 15-week challenge pigs also showed reduced variation in weight.


Variation seen as the tighter grouping of the interquartile range (IQR) in the vaccinates (blue) versus non-vaccinates (gray).


Ingelvac Provenza® for swine protection
Ingelvac Provenza® is a bivalent live attenuated influenza vaccine (LAIV) that demonstrates broad cross-protection against the ever-evolving threat of IAV-S. This in-field evaluation supports Ingelvac Provenza® as a strong foundation for respiratory health.

For more information on how Ingelvac Provenza® can help bring measurable value to your herd's health, visit IngelvacProvenza.com.

Disclaimer

WELCOME TO INGELVACPROVENZA.COM

Are you located within the United States of America?
ARE YOU A VETERINARIAN?

This is a required field

This website is an international information resource intended for veterinarians who are interested in information about Ingelvac Provenza® and influenza A virus in swine.

While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that the registration status and approved product label may not be the same in different countries.

INGELVAC Provenza® IS ONLY CURRENTLY LICENCED IN THE UNITED STATES OF AMERICA. Information on this website is derived from the product label in the USA.

By checking the box below, you are declaring and confirming that you are a veterinarian professional and that you have read and understood this disclaimer.

You must accept the terms and conditions and data policy to enter the website

Ingelvac Provenza is a trademark of Boehringer Ingelheim Vetmedica GmbH. © 2018 Boehringer Ingelheim Vetmedica, Inc.